跳至主要内容
临床试验/NCT03196271
NCT03196271已完成不适用

Evaluating the Tolerance, Compliance, Acceptability and Safety of Ketocal 2.5:1 LQ, a Nutritionally Complete Liquid Feed for Use as Part of the Ketogenic Diet (KD) in Children 8+ Years, Adolescents and Adults With Intractable Epilepsy or Other Disorders Where the KD is Indicated

Nutricia UK Ltd9 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2017年1月4日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
26
试验地点
9
主要终点
Gastrointestinal tolerance

研究概览

简要总结

An evaluation of the tolerance, compliance, acceptability and safety of a nutritionally complete liquid feed for use as part of the ketogenic diet (KD) in children 8+ years, adolescents and adults with intractable epilepsy or other disorders where the KD is indicated.

详细描述

An evaluation of the tolerance, compliance, acceptability and safety of a nutritionally complete liquid feed for use as part of the ketogenic diet (KD) in children 8+ years, adolescents and adults with intractable epilepsy or other disorders where the KD is indicated.

Study is conducted over 59 days:

3 day baseline period - Patient continues on whatever dietary regimen they were on before joining the study (this may be a ketogenic diet for existing patients).

28 day control period - Patient begins ketogenic diet (if they are not already on one), and continues this for 28 days WITHOUT the study product. Patients already on a ketogenic diet continue this as normal.

28 day intervention period - A set amount of the study product is incorporated into the patient's ketogenic diet.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
8 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Male or female
  • •8 years of age or older
  • •Diagnosed with intractable epilepsy or another disorder where the KD is indicated
  • •Motivated to follow the KD for at least the duration of the trial period
  • •Either currently on a KD, or referred to start a KD
  • •Likely to benefit from Ketocal 2.5:1
  • •Written informed consent from patient and/or parent/carer, or completed consultee declaration form
  • •Willing to take finger prick blood samples to measure ketone levels

排除标准

  • •Being pregnant or planning pregnancy
  • •Requiring parenteral nutrition
  • •Major hepatic or renal dysfunction
  • •Participation in other clinical intervention studies within 1 month prior to entry of this study
  • •Allergy to any of the study product ingredients
  • •Investigator concern around willingness/ability of patient or parent/carer to comply with protocol requirements
  • •Any contraindications for the use of the ketogenic diet
  • •Significantly underweight (Body Mass Index <18.5)

研究组 & 干预措施

Study arm

Other

One single arm, consisting of a 3 day baseline period, a 28 day control period and a 28 day intervention period (Ketocal 2.5:1), in that order.

干预措施: Ketocal 2.5:1 (Dietary Supplement)

结局指标

主要结局

Gastrointestinal tolerance

时间窗: Throughout study (59 days)

GI tolerance will be recorded throughout the study via standardised questionaire

次要结局

  • Acceptability and Ease of Use(Measured on day 28 to represent 4 week baseline period, and also measured on day 59 (reflecting 4 week intervention period))
  • Compliance with feed prescription(Throughout intervention period (28 days))
  • Nutrient intake(Throughout study (59 days))
  • Adverse events and Seizures(Throughout study (59 days))
  • Height(59 days (measured at start (day 1), middle (day 31) and end of this period (day 59)))
  • Weight(59 days (measured at start (day 1), middle (day 31) and end of this period (day 59)))
  • Ketone levels(59 days.)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验